Polaryx Therapeutics Inc. Common Stock (PLYX)
Stock · NASDAQ · Health Care
$2.07as of 8/28/2026
Price chart
Open in TradingViewActive signals
Resistance level
$2.19
Industry
Biotechnology: Pharmaceutical Preparations
About PLYX
Polaryx Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal storage disorders in the United States. Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-300, a preclinical st…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 2
- Website
- polaryx.com
Fundamentals
- 1-day range
- $2.22$2.68
- Market cap
- $110.66M
- P/E (trailing)
- —
- P/E (forward)
- —
- EPS (trailing)
- $-0.14
- Dividend yield
- —
- Beta
- —
- Avg. volume
- 196.4K
52-week range
$1.86$48.91
Forecasts
4 analyst ratings
Buy 100%
Hold 0%
Sell 0%
1-year price forecast
High
$10
+384.3%
Median
$7
+239.0%
Low
$6
+190.6%
Polaryx Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- PLYXPolaryx Therapeutics Inc. Common Stock$2.07▼ 2.13%Market cap $110.66MP/E —$1.86$48.91
- NRXPNRX Pharmaceuticals Inc. Common Stock$3.54▼ 2.21%Market cap $111.95MP/E —
- COYACoya Therapeutics Inc. Common Stock$4.59▼ 5.56%Market cap $107.43MP/E —$3.71$7.75
- RFLRafael Holdings Inc. Class B Common Stock$2.52▲ 6.33%Market cap $105.04MP/E —$1.12$3.96
- BGMBGM Group Ltd. Class A Ordinary Shares$0.3251▲ 11.34%Market cap $118.62MP/E —$0.2287$11.8
- PMNProMIS Neurosciences Inc. Common Shares (ON)$13.79▼ 1.43%Market cap $119.54MP/E —$6.27$27.4
- GNLXGenelux Corporation Common Stock$2.66▼ 7.64%Market cap $121.07MP/E —$2.29$8.54
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| PLYX Polaryx Therapeutics Inc. Common Stock | $110.66M | — | $2.07 | ▼ 2.13% | $1.86$48.91 |
| NRXP NRX Pharmaceuticals Inc. Common Stock | $111.95M | — | $3.54 | ▼ 2.21% | |
| COYA Coya Therapeutics Inc. Common Stock | $107.43M | — | $4.59 | ▼ 5.56% | $3.71$7.75 |
| RFL Rafael Holdings Inc. Class B Common Stock | $105.04M | — | $2.52 | ▲ 6.33% | $1.12$3.96 |
| BGM BGM Group Ltd. Class A Ordinary Shares | $118.62M | — | $0.3251 | ▲ 11.34% | $0.2287$11.8 |
| PMN ProMIS Neurosciences Inc. Common Shares (ON) | $119.54M | — | $13.79 | ▼ 1.43% | $6.27$27.4 |
| GNLX Genelux Corporation Common Stock | $121.07M | — | $2.66 | ▼ 7.64% | $2.29$8.54 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Polaryx Therapeutics Says It Remains On Track To Initiate Phase 2 SOTERIA Basket Trial Of PLX-200 In Four Pediatric Lysosomal Storage Disorders In Q4 2026benzinga · 8/25/2026
- This Vail Resorts Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For ThursdayBenzinga · 8/13/2026
- Raymond James Initiates Coverage On Polaryx Therapeutics with Strong Buy Rating, Announces Price Target of $6Benzinga · 8/13/2026
- 12 Health Care Stocks Moving In Friday's Pre-Market SessionBenzinga · 7/31/2026
Insider Activity
Insider Actions →Acquired
88.5K
Disposed
0
- Alex Keun Mo Yang · May 27, 2026 · Buy88.5K @ $4.07
Institutional Ownership
March 31, 2026
- Total shares held
- 2.16M
- Total value held
- $16.30M
- Institutional holders
- 12
Top holders this quarter
- Unknown1.66M
- Unknown170.7K
- Unknown127.5K
- Unknown58.1K
- Unknown41.0K
- Unknown28.0K
- Unknown25.9K
- Unknown13.5K
- Unknown13.5K
- Unknown12.4K
See the full, filterable feed with live charts on the MarketWall dashboard.